With the development of molecular subtype in lung cancer, NSCLC patients with EGFR-WT had been identified to carry several new “driver mutations”, including KRAS, HER2, and BRAF mutations, as well as ALK, ROS1, and RET gene fusion. This evidence concerns the gene KRAS and non-small cell lung carcinoma.